Gubra A/S

Amylyx Advances AMX0318 as Long-Acting GLP-1 Receptor Antagonist for Post-Bariatric Hypoglycemia

- Amylyx Pharmaceuticals has nominated AMX0318, a novel long-acting GLP-1 receptor antagonist, as a development candidate for post-bariatric hypoglycemia and other rare diseases. - The compound was identified through collaboration with Gubra A/S using their AI-driven streaMLine platform and demonstrated robust chemical stability, strong in vitro potency, and favorable pharmacokinetic properties. - IND-enabling studies are expected to begin in 2026 with an IND submission targeted for 2027, while Amylyx continues its Phase 3 LUCIDITY trial of avexitide. - Under the collaboration terms, Gubra is eligible for over $50 million in development milestones plus mid-single digit royalties, with $4 million in immediate milestone payments.